Mitogen-activated protein kinase kinase 6 (MAP2K6)

Mitogen-activated protein kinase kinase 6 (MAP2K6), also known as MKK6, is a dual-specificity protein kinase that serves as a critical upstream activator in the p38 MAPK signaling pathway (UniProt: P52564). It specifically phosphorylates and activates p38 MAP kinases in response to various environmental stresses, including UV radiation, osmotic shock, and oxidative stress, as well as pro-inflammatory cytokines like TNF-alpha (PubMed: 8622669). This activation triggers a cascade of downstream effects that regulate gene expression, cell cycle progression, and apoptosis (NCBI Gene: 5608). In pathological states, MAP2K6 is frequently dysregulated; its overactivation is linked to chronic inflammatory diseases such as rheumatoid arthritis and Crohn's disease, and it plays a complex role in oncology, where it can act as either a tumor suppressor or a promoter depending on the tissue context (PubMed: 28651083). Therapeutic strategies targeting MAP2K6 aim to modulate the p38 pathway more selectively than direct p38 inhibitors, which have often faced challenges in clinical trials due to toxicity (PubMed: 31430475). Experimental small-molecule inhibitors like MKK6-IN-1 are currently being used in research to explore the potential of MAP2K6 as a drug target for inflammatory and fibroproliferative disorders (PubMed: 32810218).

Other names

MKK6MAPKK6MEK6SAPK kinase 3SKK3MAP kinase kinase 6

Inhibition of the dual-specificity kinase activity of MAP2K6, preventing the phosphorylation and subsequent activation of downstream p38 mitogen-activated protein kinases (MAPKs).